Therefore, in the development of new drugs for cancer treatment, EGFR and its signaling components can be used as targets, such as chimeric monoclonal antibodies (panitumumab and cetuximab) [8] and TKIs (gefitinib, erlotinib, and afatinib) [9–11]. Here, EGFR is linked to cancer.